Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evofosfamide and ARSI in Castration-Resistant Prostate Cancer
NCT06836726Phase 2Not yet recruiting
- Sponsor
- University Health Network
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of evofosfamide in castration-resistant prostate cancer (CRPC), sponsored by University Health Network. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
evofosfamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT06836726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06836726.